Recent developments in gene-directed enzyme prodrug therapy (GDEPT) for cancer

Current Opinion in Molecular Therapeutics

Volumn 1, Issue 4, 1999, Pages 480-486

  Niculescu Duvaz, Ion ^a   Cooper, Robert G ^a   Stribbling, Stephen M ^a   Heyes, James A ^a   Metcalfe, Jaqueline A ^a   Springer, Caroline J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOANTHRACENE; 4 IPOMEANOL; 4 [(2 CHLOROETHYL)(2 MESYLOXYETHYL)AMINO]BENZOYLGLUTAMIC ACID; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; 6 METHYLPURINE 2' DEOXYRIBONUCLEOSIDE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALKYNE DERIVATIVE; CARBOXYLESTERASE; CARBOXYPEPTIDASE G2; CYTOCHROME P450 2B1; CYTOCHROME P450 2B6; CYTOCHROME P450 4B1; CYTOCHROME P450 ISOENZYME; CYTOSINE DEAMINASE; DEXTRO ALANINE; DEXTRO AMINO ACID OXIDASE; ENZYME; FLUCYTOSINE; GANCICLOVIR; GANCICLOVIR DERIVATIVE; GANCICLOVIR ELAIDIC ACID ESTER; INDOLE DERIVATIVE; IRINOTECAN; NITROREDUCTASE; PRODRUG; PURINE DERIVATIVE; PURINE NUCLEOSIDE PHOSPHORYLASE; THYMIDINE KINASE; UNCLASSIFIED DRUG; VIRUS VECTOR;

CANCER CELL DESTRUCTION; DRUG ACTIVATION; GENE TARGETING; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; NONHUMAN; REVIEW; SOLID TUMOR; SUICIDE GENE; TREATMENT OUTCOME;

EID: 0032827040     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Niculescu-Duvaz I, Spooner R, Marais R, Springer CJ: Gene-directed enzyme prodrug therapy. Bioconjug Chem (1998) 9:4-22.
2. Martin LA, Pandha HS, Sikora K: Genetic prodrug activation therapy: a novel treatment of cancer. Drugs Fut (1998) 23:279-290.
3. Bilbao G, Contreras JL, Gómez-Navarro J, Curiel DT: Improving adenoviral vectors for cancer gene therapy. Tumor Targeting (1998) 3:59-79.
4. Kanai F, Hamada H, Shiratori Y, Omata M: Adenovirus-mediated enzyme-prodrug therapy for cancer. Cancer J (1997) 10:301-305.
5. Bobbins PD, Ghivizzani SC: Viral vectors for gene therapy. Pharmacol Ther (1998) 80:35-47.
6. Moriuchi S, Oligino T, Krisky D, Marconi P, Fink D, Cohen J, Glorioso JC: Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coexpression of human tumor necrosis factor-α and herpes simplex virus thymidine kinase. Cancer Res (1998) 58:5731-5737.
7. Nguyen JT, Wu P, Clouse ME, Hlatky L, Terwilliger EF: Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res (1998) 58:5673-5677.
8. Wolff G, Kömer IJ, Schumacher A, Arnold W, Dörken B, Mapara MY: Er vivo breast cancer cell purging by adenovirus-mediated cytosine deaminase gene transfer and short-term incubation with 5-fluorocytosine completely prevents tumor growth after transplantation. Hum Gene Ther (1998) 9:2277-2284.
9. van der Eb MM, Cramer SJ, Vergouwe Y, Schagen FHE, van Krieken JHJM, van der Eb AJ, Rinkes IHM, van de Velde CJH, Hoeben RC: Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration. Gene Ther (1998) 5:451-458.
10. Amalfitano A, Hauser MA, Hu H, Serra D, Begy CR, Chamberlain JS: Production and characterization of improved adenovirus vectors with E1, E2b, and E3 genes deleted. J Virol (1998) 72:926-933.
11. Gao GP, Yang Y, Wilson JM: Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol (1996) 70:8934-8943.
12. Lanuti M, Gao G-P, Force SD, Chang MY, El Kouri C, Amin KM, Hughes JV, Wilson JM, Kaiser LR, Albelda SM: Evaluation of an E1E4-deleted adenovirus expressing the herpes simplex thymidine kinase suicide gene in cancer gene therapy. Hum Gene Ther (1999) 10:463-475.
13. Rogers BE, Douglas JT, Sosnowski BA, Ying W, Pierce G, Buchsbaum DJ, Manna DD, Baird A, Curiel DT: Enhanced in vivo gene delivery to human ovarian cancer xenografts utilizing a tropism-modified adenovirus vector. Tumor Targeting (1998) 3:25-31.
14. Wildner O, Morris JC, Vahanian NN, Ford H Jr, Ramsey WJ, Blaese RM: Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ther (1999) 6:57-62.
15. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH: A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther (1998) 9:1323-1333.
16. Cao X, Ju DW, Tao Q, Wang J, Wan T, Wang BM, Zhang W, Hamada H: Adenovirus-mediated GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorocytosine administration elicit more potent antitumor response in tumor-bearing mice. Gene Ther (1998) 5:1130-1136.
17. Colin M, Harbottle RP, Knight A, Kornprobst M, Cooper RG, Miller AD, Trugnan G, Capeau J, Coutelle C, Brahimi-Horn MC: Liposomes enhance delivery and expression of an RGD-oligolysine gene transfer vector in human tracheal cells. Gene Ther (1998) 5:1488-1498.
18. Konishi H, Ochiya T, Chester KA, Begent RHJ, Muto T, Sugimura T, Terada M: Targeting strategy for gene delivery to carcinoembryonic antigen-producing cancer cells by retrovirus displaying a single-chain variable fragment antibody. Hum Gene Ther (1998) 9:235-248.
19. Uckert W, Kammertöns T, Haack K, Qin Z, Gebert J, Schendel DJ, Blankenstein T: Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo. Hum Gene Ther (1998) 9:855-865.
20. Maria BL, Friedman T: Gene therapy for pediatric brain tumor. (1997) Semin Pediatr Neurol (1997) 4:333-339.
21. Miller AD: Cationic liposomes for gene therapy. Angew Chem Int Ed Engl (1998) 37:1768-1785.
22. Rainov NG, Dobberstein K-U, Sena-Esteves M, Heminger U, Kramm CM, Philpot RM, Hilton J, Chiocca EA, Breakefield XO: New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Hum Gene Ther (1998) 9:1261-1273.
23. Kojima A, Hackett NR, Ohwada A, Crystal RG: In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors. J Clin Invest (1998) 101:1789-1796.
24. Kojima A, Hackett NR, Crystal RG: Reversal of CPT-11 resistance of lung cancer cells by adenovirus-mediated gene transfer of the human carboxylesterase cDNA. Cancer Res (1998) 58:4368-4374.
25. Stegman LD, Zheng H, Neal ER, Ben-Yoseph O, Pollegioni L, Pilone MS, Ross BD: Induction of cytotoxic oxidative stress by D-alanine in brain tumor cells expressing Rhodotorula gracilis D-amino acid oxidase: A cancer gene therapy strategy. Hum Gene Ther (1998) 9:185-193.
26. Niculescu-Duvaz D, Niculescu-Duvaz I, Friedlos F, Martin J, Spooner R, Davies L, Marais R, Springer CJ: Self-immolative nitrogen mustard prodrugs for suicide gene therapy. J Med Chem (1998) 41:5297-5309.
27. Niculescu-Duvaz I, Niculescu-Duvaz D, Friedlos F, Spooner R, Martin J, Marais R, Springer CJ: Self-immolative anthracycline prodrugs for suicide gene therapy. J Med Chem (1999) submitted.
28. Denny WA, Wilson WR: The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies. J Pharm Pharmacol (1998) 50:387-394.
29. Balzarini J, Degréve B, Andrei, G, Neyts J, Sandvold M, Myhren F, de Clerq E: Superior cytostatic activity of the ganciclovir elaidic acid ester due to the prolonged intracellular retention of ganciclovir anabolites in herpes simplex virus type 1 thymidine kinase gene-transfected tumor cells. Gene Ther (1998) 5:419-426.
30. Encell LP, Landis DM, Loeb LA: Improving enzymes for gene therapy. Nature Biotechnol (1999) 17:143-147.
31. Tiraby M, Cazaux C, Baton M, Drocourt D, Reynes J-P, Tiraby G: Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine. FEMS Microbiol Lett (1998) 167:41-49.
32. Martiniello-Wilks R, Garcia-Aragon J, Daja MM, Russell P, Both GW, Molloy PL, Lockett LJ, Russell PJ: In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. Hum Gene Ther (1998) 9:1617-1626.
33. Huthes BW, King SA, Allan PW, Parker WB, Sorscher EJ: Cell to cell contact is not required for bystander cell killing by Escherichia coli purine nucleoside phosphorylase. J Biol Chem (1998) 273:2322-2328.
34. Kuriyama S, Masui K, Sakamoto T, Nakatani T, Kikukawa M, Tsujinoue H, Mitora A, Yamazaki M, Yoshiji H, Fukui H, Ikenaka K, Mullen CA, Tsujii T: Bystander effect caused by cytosine deaminase gene and 5-fluorocytosine in vitro is substantially mediated by generated 5-fluorouracil. Anticancer Res (1998) 18:3399-3406.
35. Touraine RL, Ishii-Morita H, Ramsey WJ, Blaese RM: The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication. Gene Ther (1998) 5:1705-1711.
36. Touraine RL, Vahanian N, Ramsey WJ, Blaese RM: Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions. Hum Gene Ther (1998) 9:2385-2391.
37. Imaizumi K, Hasegawa Y, Kawabe T, Emi N, Saito H, Naruse K, Shimokata K: Bystander tumoricidal effect and gap junctional communication in lung cancer cells. Am J Respir Cell Mol Biol (1998) 18:205-212.
38. Boucher PD, Ruch RJ, Shewach DS: Differential ganciclovir-mediated cytotoxicity and bystander killing in human colon carcinoma cell lines expressing herpes simplex virus thymidine kinase. Hum Gene Ther (1998) 9:801-814.
39. Friedlos F, Court S, Ford M, Denny WA, Springer CJ: Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase. Gerte Ther (1998) 5:105-112.
40. Princen F, Lechanteur C, Lopez M, Rocoux G, Detroz B, Gielen J, Fillet G, Merville M-P, Bours V: Repeated cycles of retrovirus-mediated HSVtk gene transfer plus ganciclovir increase survival of rats with peritoneal carcinomatosis. Gene Ther (1998) 5:1054-1060.
41. Mawatari F, Tsuruta S, Ido A, Ueki T, Nakao K, Kato Y, Tamaoki T, Ishii N, Nakata K: Retrovirus-mediated gene therapy for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by human α-fetoprotein enhancer directly linked to its promoter. Cancer Gene Ther (1998) 5:301-306.
42. Rainov NG, Dobberstein K-U, Heidecke V, Dorant U, Chase M, Kramm CM, Chiocca EA, Breakefield XO: Long-term survival in a rodent brain tumor model by bradykinin-enhanced intra-arterial delivery of a therapeutic herpes simplex virus vector. Cancer Gene Ther (1998) 5:158-162.
43. Siders WM, Halloran PJ, Fenton RG: Melanoma-specific cytotoxicity induced by a tyrosinase promoter-enhancer/herpes simplex virus thymidine kinase adenovirus. Cancer Gene Ther (1998) 5:281-291.
44. Duflot-Dancer A, Piccoli C, Rolland A, Yamasaki H, Mesnil M: Long-term connexin-mediated bystander effect in highly tumorigenic human cells in vivo in herpes simplex virus thymidine kinase/ganciclovir gene therapy. Gene Ther (1998) 5:1372-1378.
45. Rosolen A, Frascella E, di Francesco C, Todesco A, Petrone M, Mehtali M, Zacchello F, Zanesco L, Scarpa M: In vitro and in vivo antitumor effects of retrovirus-mediated herpes simplex thymidine kinase gene-transfer in human medulloblastoma. Gene Ther (1998) 5:113-120.
46. Wei MX, Bougnoux P, Sacré-Salem B, Peyrat M-B, Lhuillery C, Salzmann J-L, Klatzmann D: Suicide gene therapy of chemically Induced mammary tumor in rat: Efficacy and distant bystander effect. Cancer Res (1998) 58:3529-3532.
47. Hall SJ, Sanford MA, Atkinson G, Chen S-H: Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer. Cancer Res (1998) 58:3221-3225.
48. Poptani H, Puumalainen A-M, Gröhn OH, Loimas S, Kainulainen R, Ylä-Herttuala S, Kauppinen RA: Monitoring thymidine kinase and ganciclovir-induced changes in rat malignant glioma in vivo by nuclear magnetic resonance imaging. Cancer Gene Ther (1998) 5:101-109.
49. 1H nuclear magnetic resonance diffusion spectroscopy of BT4C rat glioma during thymidine kinase-mediated gene therapy in vivo: identification of apoptotic response. Cancer Res (1998) 58:3791-3799.
50. Tjuvajev JG, Avril N, Oku T, Sasajima T, Miyagawa T, Joshi R, Safer M, Beattie B, DiResta G, Daghighian F, Augensen F, Koutcher J, Zweit J, Humm J, Larson SM, Finn R, Blasberg R: Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res (1998) 58:4333-4341.
51. Topf N, Worgall S, Hackett NR, Crystal RG: Regional 'prodrug' gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma. Gene Ther (1998) 5:507-513.
52. Löhr M, Müller P, Karle P, Stange J, Mitzner S, Jesnowski R, Nizze H, Nebe B, Liebe S, Salmons B, Günzburg WH: Targeted chemotherapy by intratumoral injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450. Gene Ther (1998) 5:1070-1078.
53. Jounaidi Y, Hecht JED, Waxman DJ: Retroviral transfer of human cytochromes P450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Res (1998) 58:4391-4401.
54. Marais R, Spooner RA, Stribbling SM, Light Y, Martin J, Springer CJ: A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy. Nature Biotechnol (1997) 15:1373-1377.
55. McNeish IA, Green NK, Gilligan MG, Ford MJ, Mautner V, Young LS, Kerr DJ, Searle PF: Virus directed enzyme prodrug therapy for ovarian and pancreatci cancer using retrovirally delivered E. coli nitroreductase and CB1954. Gene Ther (1998) 5:1061-1069.
56. Li Y, Pong RC, Bergelson JM, Hall MC, Sagalowsky AI, Tseng CP, Wang Z, Hsieh JT: Loss of adenoviral receptor expression in human bladder cancer cells. Cancer Res (1999) 59:325-330.
57. Sterman DH, Kasier LR, Albelda SM: Gene therapy for malignant pleural mesothelioma. Hematol Oncol Clin North Am (1998) 12:553-568.
58. Zwacka RM, Dunlop MG: Gene therapy for colon cancer. Hematol Oncol Clin North Am (1998) 12:595-615.
59. Dranoff G: Cancer gene therapy: connecting basic research with clinical inquiry. J Clin Oncol (1998) 16:2548-2556.
60. Wildner O, Blaese M, Morris JC: Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res (1999) 59:410-413.
61. Morel A, de La Coste A, Fernandez N, Berson A, Kaybanda M, Molina T, Briand P, Haddada H, Guillet JG, Antonie B, Viguier M, Khan A: Does preventive vaccination with engineered tumor cells work in cancer-prone transgenic mice? Cancer Gene Ther (1998) 5:92-100.